Tirzepatide for Weight Loss: Clinics, Cost & What to Know

Tirzepatide is a dual GIP/GLP-1 receptor agonist and the FDA reference file describes it as the first-in-class dual incretin. It acts on both GIP and GLP-1 receptors, which is the key mechanism difference from semaglutide.

For weight loss, the relevant FDA-approved branded product is Zepbound, which was approved in November 2023 for chronic weight management in adults who meet the labeled BMI criteria. Mounjaro is FDA-approved for type 2 diabetes, not weight loss.

The SURMOUNT-1 trial, 2022 reported average body-weight loss of 20.9% at the highest 15 mg dose over 72 weeks versus 3.1% with placebo. The reference file also lists SURMOUNT-2 and SURMOUNT-3, plus SURPASS-2, which compared tirzepatide against semaglutide 1 mg in diabetes care.

Per the FDA label, Zepbound starts at 2.5 mg weekly and escalates monthly, with common maintenance doses of 10 mg or 15 mg weekly. Mounjaro follows the same escalation pattern in the reference notes.

The FDA reference lists branded tirzepatide products at roughly $1,000 to $1,100 per month retail for both Zepbound and Mounjaro.

Prices vary by pharmacy and location, and the actual monthly total may also depend on clinic fees, insurance rules, and pharmacy channel.

Manufacturer savings programs may be available for some branded tirzepatide prescriptions, but terms vary and patients should verify current eligibility.

Prices vary by pharmacy, location, and clinic structure.

Tirzepatide has stronger weight-loss numbers in the reference file than semaglutide in separate trials, but the file also warns against over-reading cross-trial comparisons.

The cleanest comparison is mechanism, labeled use, side-effect profile, and access: tirzepatide works on two incretin pathways, while semaglutide works on one. Coverage, tolerability, and the exact branded product often matter just as much as the raw headline number.